A Randomized, Open-label, Two Sequence, Two-period Cross-over Study Evaluating the Relative Bioavailability of ABSK091 Single Dose Between Fed and Fasted States in Healthy Subjects
Latest Information Update: 12 Sep 2022
At a glance
- Drugs ABSK 091 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Abbisko Therapeutics
Most Recent Events
- 12 Sep 2022 New trial record